Back to news
  • Publications
Sep 30, 2025null min read

SKINQARE Study Highlights Benefits of Sequential Treatment with Hyaluronic Acid Injectables for Skin Quality

Published in the Aesthetic Surgery Journal, the SKINQARE study demonstrates that sequential treatment with RHA® 1 and Redensity® 1 significantly improves hydration, elasticity, and fine lines, offering long-lasting results with high patient satisfaction.

At Teoxane, our mission is to continuously push the boundaries of aesthetic medicine through innovation and science. We are pleased to share new clinical evidence from the SKINQARE study, recently published in the Aesthetic Surgery Journal, which confirms the effectiveness and safety of a sequential treatment using two hyaluronic acid (HA) fillers to improve overall skin quality.

About the SKINQARE Study
 

Conducted in Spain across multiple centers, the SKINQARE study explored how a sequential treatment plan using two TEOSYAL® products could enhance fine lines, hydration, elasticity, and skin texture in the face and neck.

  • Step 1: TEOSYAL® RHA 1, chosen for its flexibility and ability to integrate seamlessly with facial dynamics, smoothing fine lines for a more harmonious surface.
  • Step 2: TEOSYAL® PureSense Redensity 1, a non-crosslinked HA enriched with nutrients and antioxidants, designed to nourish the skin deeply, improving radiance, plumpness, and firmness.

This combined approach allowed investigators to assess how pairing skin beautification with redensification could deliver more comprehensive and longer-lasting results.

Key Results

  • Strong efficacy: 87% of patients were rated “improved” or “much improved” two months after treatment, exceeding the study’s success criteria. For smiling lines specifically, improvement reached over 92%.
  • Extended benefits: Adding Redensity® 1 helped prolong improvements in hydration, elasticity, and smoothness for up to 5 months.
  • High satisfaction: More than 80% of patients in the RHA 1 + R1 group reported being “very satisfied” at 5 months: twice as many as those treated with RHA 1 alone.
  • Excellent tolerability: All reported side effects were mild to moderate and resolved within days, reinforcing the trusted safety profile of the TEOSYAL® range.

 

Expert Perspective


“The SKINQARE study showcases the power of combining hydration and surface refinement in a single treatment journey,” explains Dr Paula Rosso. “ By integrating RHA 1 with Redensity 1, practitioners can provide patients with a more holistic and long-lasting solution for youthful, radiant skin.”

 

Clinical Significance


The study confirms TEOSYAL® RHA 1 as an effective treatment for skin beautification, while highlighting the added value of Redensity® 1 as a complementary step to further enhance skin quality and extend results. Together, they offer practitioners a flexible approach tailored to patient needs: from fine line correction to deep skin revitalization.

About Redensity® 1 and RHA® 1

  • TEOSYAL® RHA 1: Designed for areas requiring flexibility, it supports hydration and elasticity while adapting to facial expressions.
  • TEOSYAL® PureSense Redensity 1: A unique HA-based injectable enriched with amino acids, vitamins, and antioxidants to improve skin health and radiance.